Aldeyra Therapeutics Receives Orphan Drug Designation from the U
ALDX: Aldeyra Therapeutics, Inc.
2021-08-04 08:00:00
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
2021-08-04 08:00:00
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa